Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up

Background and Objective: Non-motor symptoms (NMS) progress in different ways between Parkinson's disease (PD) patients. The aim of the present study was to (1) analyze the change in global NMS burden in a PD cohort after a 2-year follow-up, (2) to compare the changes with a control group, and (3) to identify predictors of global NMS burden progression in the PD group. Material and Methods: PD patients and controls, recruited from 35 centers of Spain from the COPPADIS cohort from January 2016 to November 2017, were followed-up with after 2 years. The Non-Motor Symptoms Scale (NMSS) was administered at baseline (V0) and at 24 months +/- 1 month (V2). Linear regression models were used for determining predictive factors of global NMS burden progression (NMSS total score change from V0 to V2 as dependent variable). Results: After the 2-year follow-up, the mean NMS burden (NMSS total score) significantly increased in PD patients by 18.8% (from 45.08 +/- 37.62 to 53.55 +/- 42.28; p < 0.0001; N = 501; 60.2% males, mean age 62.59 +/- 8.91) compared to no change observed in controls (from 14.74 +/- 18.72 to 14.65 +/- 21.82; p = 0.428; N = 122; 49.5% males, mean age 60.99 +/- 8.32) (p < 0.0001). NMSS total score at baseline (beta = -0.52), change from V0 to V2 in PDSS (Parkinson's Disease Sleep Scale) (beta = -0.34), and change from V0 to V2 in NPI (Neuropsychiatric Inventory) (beta = 0.25) provided the highest contributions to the model (adjusted R-squared 0.41; Durbin-Watson test = 1.865). Conclusions: Global NMS burden demonstrates short-term progression in PD patients but not in controls and identifies worsening sleep problems and neuropsychiatric symptoms as significant independent predictors of this NMS progression.

Automated summary

The study found a significant increase in NMS burden in Parkinson's disease patients over 2 years, while no change was observed in the control group. Worsening sleep problems and neuropsychiatric symptoms were identified as significant independent predictors of this NMS progression.